BANGALORE, June 15, 2021 – Mylan, a Viatris company, announced that it will be distributing AmBisome^® (Liposomal Amphotericin B Injection 50mg) in global packs containing 10 vials each, manufactured by Gilead and imported into India by Mylan. This will be supplied to Government institutions, hospitals and distributors.

The decision was taken in the backdrop of the current situation of Mucormycosis in the country, to ensure the smooth and timely supply of drugs to the patients.

AmBisome^® vials will be sold in multiples of 10 vials in global packs, with a Maximum Retail Price of Rs. 7,814/- per vial. Based on the GST exemption for Liposomal Amphotericin-B announced by the Government of India, the MRP of AmBisome^® will be revised downwards to reflect the GST exemption benefit. This revised MRP will be valid for the entire duration of GST exemption till 30 September 2021, as per the recent announcement issued by the Government.

Liposomal amphotericin B has been recommended by Global and Indian guidelines as First-line treatment for the management of mucormycosis. Its first line usage is strongly supported across all patterns of organ involvement.

Mylan is working closely with the Government to accelerate supplies of AmBisome^® to help meet the evolving patient needs in India.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway^®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.